Search

What an EHA Bilateral Collaborative Grant supports

Our EHA Bilateral Collaborative Grant supports basic and translational lab-based research in hematology. To reflect the collaborative spirit of the grant, the budget must be divided 50:50 between the two PIs.

Read more

EHA: Bridging Breakthroughs in Hematology

The European Hematology Association (EHA) has undergone a remarkable transformation over the past two years, positioning itself as a future-ready organization dedicated to addressing the needs of the European hematology community.

Read more

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Highlights of Past EHA (HOPE) Latin America (LA) 2022 - report

November 17-19, 2022 – Barranquilla, Colombia

Meeting chairs:
D McLornan, Vice-Chair Global Outreach Program Committee, European Hematology Association (EHA)
V Abello Polo, President, Asociación Colombiana de Hematología y Oncología (ACHO)

This year, the HOPE LA meeting was held in collaboration with the Asociación Colombiana…

Read more

Recap: European Affairs and Hematology at EHA2024

As at previous congresses, the European Affairs track at EHA2024 offered opportunities to learn, exchange, and connect.

Read more

Future

You may find below an overview of the dates and locations of the future EHA Congresses.  
For information on future congresses, please contact Connect at a. congress@ehaweb.

Read more

Daratumumab, a CD38 monoclonal antibody study in advanced multiple myeloma – an open-label, dose escalation followed by open-label extension in a single-arm phase I/II study

Daratumumab is a human CD38 monoclonal antibody being tested against multiple myeloma, but it could also have potential in a broad range of other hematological diseases.

Read more